Patents Assigned to invoX Pharma Limited
-
Patent number: 12667573Abstract: Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.Type: GrantFiled: March 5, 2020Date of Patent: June 30, 2026Assignee: invoX Pharma LimitedInventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan, Subramanian Baskaran, Anjaneyulu Sheri, Dillon Cleary, Ron Mastrolia, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Vishal Nair, Leena Praba Suppiah
-
Patent number: 12534534Abstract: The present application relates to antibody molecules that bind CD137. The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer and infectious diseases.Type: GrantFiled: July 12, 2019Date of Patent: January 27, 2026Assignee: INVOX PHARMA LIMITEDInventors: Sarka Pechouckova, Francisca Wollerton, Miguel Gaspar
-
Publication number: 20250368730Abstract: The present application relates to antibody molecules that bind mesothelin (MSLN). The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer.Type: ApplicationFiled: May 2, 2025Publication date: December 4, 2025Applicant: INVOX PHARMA LIMITEDInventors: Jose Munoz-Olaya, Remi Fertin, Francisca Wollerton, Mihriban Tuna, Neil Brewis
-
Publication number: 20250361312Abstract: The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: ApplicationFiled: May 8, 2025Publication date: November 27, 2025Applicant: INVOX PHARMA LIMITEDInventors: Mihriban Tuna, Miguel Gaspar, Sandra Uhlenbroich, Katy Everett, Delphine Buffet
-
Publication number: 20250346679Abstract: The present application relates to antibody molecules that bind both PD-L1 and CD137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.Type: ApplicationFiled: May 23, 2025Publication date: November 13, 2025Applicant: INVOX PHARMA LIMITEDInventors: Matthew Lakins, Jose Munoz-Olaya, Francisca Wollerton, Sarah Batey, Mihriban Tuna, Alexander Koers
-
Publication number: 20250270324Abstract: An antibody molecule, or antigen-binding fragment thereof capable of binding specifically to PD-L1.Type: ApplicationFiled: January 31, 2025Publication date: August 28, 2025Applicant: INVOX PHARMA LIMITEDInventors: Francisca Wollerton, Matthew Lakins, Mateusz Wydro, Sachin Surade, Michael Dyson
-
Patent number: 12390668Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.Type: GrantFiled: June 30, 2023Date of Patent: August 19, 2025Assignee: invoX Pharma LimitedInventor: Radhakrishnan P. Iyer
-
Patent number: 12344672Abstract: The present application relates to antibody molecules that bind both PD-L1 and CD 137 and are able to induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1, and a CD137 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer.Type: GrantFiled: July 12, 2019Date of Patent: July 1, 2025Assignee: INVOX PHARMA LIMITEDInventors: Matthew Lakins, Jose Munoz-Olaya, Francisca Wollerton, Sarah Batey, Mihriban Tuna, Alexander Koers
-
Patent number: 12325742Abstract: The present application relates to antibody molecules that bind mesothelin (MSLN). The antibody molecules find application in the treatment and diagnosis of diseases and disorders, such as cancer.Type: GrantFiled: July 12, 2019Date of Patent: June 10, 2025Assignee: INVOX PHARMA LIMITEDInventors: Jose Munoz-Olaya, Remi Fertin, Francisca Wollerton, Mihriban Tuna, Neil Brewis
-
Patent number: 12319739Abstract: The present invention relates to antibody molecules that bind both mesothelin (MSLN) and CD137. The antibody molecules comprise a CDR-based binding site for MSLN, and a CD137 antigen-binding site located in a constant domain of the antibody molecule. The antibody molecules find application in the treatment of cancer, for example.Type: GrantFiled: July 12, 2019Date of Patent: June 3, 2025Assignee: INVOX PHARMA LIMITEDInventors: Jose Munoz-Olaya, Mihriban Tuna, Remi Fertin, Claire Reader, Francisca Wollerton, Neil Brewis
-
Patent number: 12297283Abstract: The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: GrantFiled: July 12, 2019Date of Patent: May 13, 2025Assignee: INVOX PHARMA LIMITEDInventors: Mihriban Tuna, Miguel Gaspar, Sandra Uhlenbroich, Katy Everett, Delphine Buffet
-
Patent number: 12252537Abstract: The present application relates to antibody molecules that bind and am able to agonise both CD137 and OX40. The antibody molecules comprise a CDR-based binding site for CD137, and an OX40 antigen-binding site that is located in a constant domain of the antibody molecule. The antibody molecules of the invention find application, for example, in the treatment of diseases, such as cancer and infectious diseases.Type: GrantFiled: July 12, 2019Date of Patent: March 18, 2025Assignee: INVOX PHARMA LIMITEDInventors: Mihriban Tuna, Miguel Gaspar, Michelle Morrow, Edmund Poon
-
Publication number: 20250084176Abstract: The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: ApplicationFiled: August 23, 2024Publication date: March 13, 2025Applicant: invoX Pharma LimitedInventors: Matthew Lakins, Jose Munoz-Olaya, Sarka Pechouckova, Mihriban Tuna
-
Patent number: 12247074Abstract: The present disclosure, in some aspects, provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1. The present disclosure further provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1 and a second antigen-binding site. Methods of making and/or using such antibody molecules or antigen bending fragments are also provided.Type: GrantFiled: July 12, 2019Date of Patent: March 11, 2025Assignee: INVOX PHARMA LIMITEDInventors: Francisca Wollerton, Matthew Lakins, Mateusz Wydro, Sachin Surade, Michael Dyson
-
Patent number: 12187761Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.Type: GrantFiled: January 20, 2023Date of Patent: January 7, 2025Assignee: invoX Pharma LimitedInventors: Radhakrishnan P. Iyer, Geeta Meher, Anjaneyulu Sheri, Shenghua Zhou, Sreerupa Challa, Rayomand H. Gimi, Seetharamaiyer Padmanabhan, Dillon Cleary
-
Patent number: 12187798Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: GrantFiled: November 23, 2021Date of Patent: January 7, 2025Assignee: INVOX PHARMA LIMITEDInventors: Mihriban Tuna, Francisca Wollerton van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Patent number: 12103976Abstract: The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.Type: GrantFiled: July 12, 2019Date of Patent: October 1, 2024Assignee: invoX Pharma LimitedInventors: Matthew Lakins, Jose Munoz-Olaya, Sarka Pechouckova, Mihriban Tuna
